8-K: Organogenesis Secures $130 Million in Private Placement to Fuel Growth and Repurchase Shares

Organogenesis Holdings Inc. has successfully raised $130 million through a private placement of Series A Convertible Preferred Stock to fund strategic growth initiatives and repurchase shares from existing stockholders.

Summary

• Organogenesis Holdings Inc. has entered into a subscription agreement with Avista Healthcare Partners to sell $130 million of Series A Convertible Preferred Stock in a private placement.
• The net proceeds will be used for strategic growth initiatives, including operating and commercial activities, clinical development programs, working capital, capital expenditures, and debt repayment.
• Approximately $23.5 million of the proceeds will be used to repurchase 7,421,731 shares of Class A common stock from certain directors and their affiliates at $3.1597 per share.
• The repurchase price is based on the 10-day trailing volume weighted average price of the common stock as of November 11, 2024.
• The Series A Convertible Preferred Stock is initially convertible into 263.7358 shares of common stock per $1,000 of liquidation preference, implying a conversion price of $3.79 per share.
• The conversion price represents a 20% premium to the 10-day trailing volume weighted average price of the common stock.
• The preferred stock has an 8% cumulative annual dividend, compounded quarterly, payable in cash or in kind at the company's option.
• The investors have the option to convert their preferred stock into common stock at any time, subject to certain limitations before stockholder approval.
• The company can force conversion of the preferred stock if the common stock price exceeds 200% of the conversion price for 20 of 30 consecutive trading days after November 12, 2026.
• Investors have the right to redeem their preferred stock for the liquidation preference plus accrued dividends after November 12, 2031.

Sentiment

Score: 7

Explanation: The document conveys a positive sentiment due to the successful capital raise and strategic growth plans. However, the potential for dilution and the repurchase of shares from insiders temper the overall optimism.

Positives

• The $130 million private placement provides significant capital for strategic growth initiatives.
• The company has enhanced its balance sheet and financial flexibility.
• The repurchase of shares from directors and affiliates may be seen as a positive signal of confidence.
• The conversion premium of 20% suggests a positive valuation of the company's future prospects.
• The 8% cumulative dividend on the preferred stock provides a return for investors.
• The appointment of Garrett Lustig to the board brings additional expertise and experience.

Negatives

• The repurchase of shares from directors and affiliates could be viewed negatively by some investors.
• The potential for dilution from the conversion of preferred stock into common stock exists.
• The company is required to pay an 8% cumulative dividend on the preferred stock, which could impact cash flow.
• The company is required to pay a transaction fee to Avista Capital Holdings, LP equal to 2.0% of the Purchase Price.

Risks

• The company's ability to execute its strategic growth initiatives and achieve its financial goals is subject to various risks.
• The company faces significant competition, which could adversely affect its business.
• Rapid technological change could cause the company's products to become obsolete.
• The company must convince physicians that its products are safe and effective alternatives to existing treatments.
• The company has incurred losses in the past and may incur losses in the future.
• Changes in applicable laws or regulations could impact the company's business.
• The company's ability to maintain production or obtain supply of its products in sufficient quantities to meet demand is a risk.
• The company may be adversely affected by other economic, business, and/or competitive factors.

Future Outlook

The company intends to use the net proceeds from the private placement to fund strategic growth initiatives, enhance its balance sheet, and finance stock repurchases. The company also has the ability to force conversion of the preferred stock after November 12, 2026, if the common stock price exceeds 200% of the implied conversion price for 20 of 30 consecutive trading days.

Management Comments

• Gary S. Gillheeney, Sr., President, Chief Executive Officer and Chair of the Board for Organogenesis, stated that the financing provides strategic growth capital and significantly enhances the company's balance sheet and financial flexibility.
• Thompson Dean, Chairman of Avista Healthcare Partners, expressed belief in Organogenesis' mission and stated that the investment underscores Avista's belief in the company's ability to foster advancements in regenerative medicine.

Industry Context

This announcement reflects a trend of private equity firms investing in the regenerative medicine sector, which is experiencing growth due to advancements in technology and increasing demand for innovative healthcare solutions. The investment by Avista Healthcare Partners, a firm with a strong track record in healthcare, signals confidence in Organogenesis' potential within this market.

Comparison to Industry Standards

• The 20% premium on the conversion price is a common feature in private placements of convertible preferred stock, designed to attract investors while providing a potential upside for the company.
• The 8% cumulative dividend is within the typical range for preferred stock, offering a balance between income and potential capital appreciation.
• The seven-year redemption option for the preferred stock is a standard feature, providing investors with a long-term investment horizon.
• The use of proceeds for strategic growth initiatives and debt repayment is a common practice for companies seeking to improve their financial position and expand their operations.
• The repurchase of shares from directors and affiliates is a common practice, but can be viewed with caution by some investors.
• The appointment of a board member from the investing firm is a typical condition in private equity investments, ensuring alignment of interests and providing strategic guidance.

Management Changes

Corporate Governance

Related Party Transactions

• The company will repurchase 7,421,731 shares of common stock from certain directors and their affiliates at $3.1597 per share.

Stakeholder Impact

• Shareholders may experience dilution if the preferred stock is converted into common stock.
• Employees may benefit from the company's strategic growth initiatives.
• Customers may benefit from the company's enhanced product offerings.
• Suppliers may benefit from the company's increased production and demand.
• Creditors may benefit from the company's debt repayment.

Next Steps

• The company will file a registration statement for the resale of the preferred stock and common stock issuable upon conversion.
• The company will seek stockholder approval for the issuance of common stock upon conversion of the preferred stock.
• The company will use the net proceeds to fund strategic growth initiatives and repurchase shares.
• The company will prepay approximately $62.5 million in principal and interest outstanding under the Term Loan Facility on November 13, 2024.

Key Dates

Keywords

private placement, convertible preferred stock, stock repurchase, regenerative medicine, Avista Healthcare Partners, strategic growth, wound care, surgical, sports medicine, capital raise